Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as DAVANAT
GM-CT-01 · 1 trial · 5 indications
| Name | Type | Description |
|---|---|---|
| GM-CT-01 | DRUG | IV infusion over 30 minutes of 6 Dosages escalated from 30 to 280 mg/m2, given for 4 consecutive days in a 28 days cycle. |
| 5-fluorouracil | DRUG | IV infusion over 30 minutes at Dosage of 500 mg/m2, given in-combination with GM-CT-01, for 4 consecutive days in a 28 days cycle. |
Inclusion Criteria: * The subject is able to give informed consent to participate in this trial (including all procedures and follow-up visits). * The subject is male or female at least 18 years of age. * The subject has a documented histologic or cytologic recurrent or metastatic solid tumor that ...
Top 20 of 80 competitors
GM-CT-01 is being studied in colorectal cancer and other solid tumors. It was evaluated in a Phase 1 trial that enrolled patients with colorectal, lung, breast, head and neck, and prostate cancers. It is an investigational agent and is not approved for commercial use.
GM-CT-01 targets galectin-3, a protein involved in tumor progression and immune regulation. By binding galectin-3, the small molecule is designed to interfere with galectin-3 mediated processes in cancer cells. This mechanism is being explored in solid tumor settings.
GM-CT-01 is being developed by Galectin Therapeutics Inc., a company traded on the Nasdaq under the ticker GALT. The company focuses on galectin-targeted therapies, and GM-CT-01 is one of its clinical-stage assets.
GM-CT-01 is in Phase 1 development. It has completed one Phase 1 clinical trial in patients with solid tumors. The drug remains investigational and has not been approved by the FDA for any indication.
GM-CT-01 has been studied in a single completed Phase 1 trial, NCT00054977, titled Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors. The trial enrolled 40 patients in the United States and evaluated safety in colorectal cancer and other solid tumors.